Printer Friendly

Huifeng Bio-Pharmaceutical (HFGB) Announces USD $1.1 Million Supply Agreement with DNP International Co. Inc.

XI'AN, China, Aug. 11 /Xinhua-PRNewswire-FirstCall/ -- Huifeng Bio-Pharmaceutical Technology, Inc (BULLETIN BOARD: HFGB) , a leading developer and producer of plant extracts and pharmaceutical raw materials for use in pharmaceutical, nutraceutical and food production, today announced that it has signed a major supply agreement with DNP International Co., Inc. of Santa Fe Springs, CA.

Under the terms of the agreement Huifeng is to deliver 62 metric tons of Glucuronolactone, a naturally occurring chemical compound which has become a popular additive to energy drinks, over the next six months to DNP. The total dollar amount of the contract is in excess of USD $1.1 Million.

Huifeng anticipates signing additional bi-annual contracts with DNP upon successful completion of the first agreement.

''Our agreement with DNP further demonstrates the increasing international acceptance of Huifeng products. With quality and consistency as our hallmarks, we are now becoming recognized by major US corporations for the quality and consistency of the products we develop and manufacture,'' stated company CEO Jing'An Wang. ''We are pleased to be making further inroads into the US market and hope to sign similar supply agreements with DNP and other US entities in the near future.''

About Glucuronolactone

Glucuronolactone is a naturally occurring chemical compound produced by the metabolism of glucose in the human liver. It is an important structural component of nearly all connective tissues. The most common usage for Glucuronolactone is in many energy drinks. Because most of these drinks also contain caffeine, Glucuronolactone is included because it is purported to fight fatigue and provide a sense of well-being. According to "The Merck Index" (14th edition) it is also used as detoxicant. (From Wikipedia)

About DNP International

DNP International imports and distributes raw material ingredients to manufacturers in the nutritional supplements, food, beverage, feed, cosmetics and pharmaceutical industries. Founded in 1994, DNP is one of the largest suppliers of raw materials in the United States and sources over 2,500 different ingredients. http://www.dnpint.com/

About Huifeng Bio-Pharmaceutical Technology, Inc. (HFGB)

Huifeng Bio-Pharmaceutical Technology, Inc., located in Xi'an, People's Republic of China, develops and produces plant extracts and pharmaceutical raw materials for use in pharmaceutical, nutraceutical and food production. It is the leading Chinese producer of rutin and related plant-derived chemicals in a class called flavonoids, with medicinal and other beneficial properties. Founded in 2002, Huifeng uses proprietary patented processes to extract rutin more efficiently than traditional extraction techniques. The Company is diversifying its product lines through internal development, acquisition and cooperation with scientific research organizations. http://www.hfgb.cn/
 For more information, please contact:

 Dan Carlson,
 Primary Capital LLC
 Email: DCarlson@PrimaryLLC.com

 Kelly Black, CEO
 Premier Media Services, Inc.
 Tel: +1-480-649-8224



CONTACT: Dan Carlson of Primary Capital LLC, DCarlson@PrimaryLLC.com, or Kelly Black, CEO of Premier Media Services, Inc., +1-480-649-8224, both for Huifeng

Web Site: http://www.hfgb.cn/ http://www.dnpint.com/
COPYRIGHT 2008 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2008 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Aug 11, 2008
Words:476
Previous Article:NexxNow, Inc. Licenses ACE Technology to Quebec Scope Magazine.
Next Article:The Mint Leasing, Inc. Retains RJ Falkner & Company, Inc. as Investor Relations Counsel.


Related Articles
Huifeng Bio-Pharmaceutical (HFGB) Announces No Earthquake Related Damage to Facilities.
Huifeng Bio-Pharmaceutical (HFGB) Provides Update on Current Business and COS Certification.
Huifeng Bio-Pharmaceutical (HFGB) Information to Be Available Through Standard & Poor's Market Access Program.
Huifeng Bio-Pharmaceutical (HFGB) Provides Update on COS Application Status.
Huifeng Bio-Pharmaceutical (HFGB) to Release Second Quarter 2008 Earnings Results on August 15, 2008.
Huifeng Bio-Pharmaceutical (HFGB) Reports over $5 Million in Gross Sales; Record Results for the First Half of 2008.
Huifeng Bio-Pharmaceutical (HFGB) to Attend CPhI South America 2008 Pharmaceutical Conference; The First CPhI Conference to be held in the Emerging...
Huifeng Bio-Pharmaceutical (HFGB) Enters into Letter of Intent with Xi'an Qinba Xintong Medical Ltd.
Huifeng Bio-Pharmaceutical (HFGB) Signs Exclusive Management Operating Agreement with Xi'an Qinba Xintong Medical Ltd.; HFGB to Retain Up to 70% of...
Huifeng Bio-Pharmaceutical (HFGB) Reports Record Sales and Net Income.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters